Clinical trial · Observational
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant Survivors: Reveal Linq Cancer Registry Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to better understand the following aims: 1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant 2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events 3. Aim 3: To evaluate overall implantation safety in this population
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
| Atrial Flutter | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HSCT Patients | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hematopoietic Stem Cell Transplant (HSCT) Patients
- description
- \- Patients with incidence of AF/AFL in the first 30 days of transplant
- interventionNames
- Other: HSCT Patients
Primary outcomes (1)
- measure
- Recurrent AF/AFL episodes
- timeFrame
- 1 year
- description
- Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring
Secondary outcomes (1)
- measure
- Incident Episodes of Interest
- timeFrame
- 1 year
- description
- Incident episodes of: stroke/TIA; other thromboembolic events (not stroke/TIA); Heart failure events; ischemic heart events. Overall device implantation safety.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 2. CHADS-VASc ≥ 2 3. Recovery of platelets to \>50,000 within 90 days of incident atrial fibrillation (AF) diagnosis 4. Discharge from the incident stem cell transplant (SCT) hospitalization 5. Normal sinus rhythm at the time of consent Exclusion Criteria: 1. Prior history of atrial fibrillation (AF) or atrial flutter 2. CHADS-VASc \<2 3. Platelets \<50,000 after 90 days post transplantation 4. Continued SCT hospitalization at 90 days 5. Inability to receive anticoagulation 6. AF or other arrhythmia at the time of consent 7. Current use of a class IC or III antiarrhythmic medication 8. Inability to provide informed consent/significant cognitive impairment 9. Expected survival less than one year.
References
Publications (0)
Data not yet available